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Summary 
The high-affinity receptor for immunoglobulin (Ig) E (FceRl) on mast cells and basophils plays 
a key role in IgE-mediated allergies.  FceRI is composed of one ix, one [3, and two ",/ chains, 
which are all required for cell surface expression of FceRI, but only the ci chain is involved in 
the binding to IgE. FceRI-IgE interaction is highly species specific, and rodent FceRI does not 
bind human IgE. To obtain a "humanized" animal model that responds to human IgE in aller- 
gic reactions,  transgenic mice expressing the human FceRI ix chain were generated. The hu- 
man FceRI ix chain gene with a 1.3-kb promoter region as a transgene was found to be suffi- 
cient for mast cell-specific transcription.  Cell surface expression of the human FceRI ix chain 
was indicated by the specific binding of human IgE to mast cells from transgenic mice in flow 
cytometric analyses.  Expression of the  transgenic  FceRI on bone marrow-derived mast cells 
was 4.7  ￿  104/ce11, and the human IgE-binding affinity was K d =  6.4 nM in receptor-binding 
studies using 12sI-IgE. The transgenic human FceRI ix chain was complexed with the mouse [3 
and ",/chains in immunoprecipitation studies. Cross-linking of the transgenic FceRI with human 
IgE and antigens led to mast cell activation as indicated by enhanced tyrosine phosphorylation 
of the FceRI [3 and ~/chains and other cellular proteins. Mast cell degranulation in transgenic 
mice could be triggered by human lgE and antigens, as demonstrated by [3-hexosaminidase re- 
lease in vitro and passive cutaneous anaphylaxis in vivo. The results demonstrate that the hu- 
man FceRI ix chain alone not only confers the specificity in human IgE binding, but also can 
reconstitute a functional receptor by coupling with the mouse [3 and y  chains to trigger mast 
cell activation and degranulation  in a whole  animal system. These transgenic mice "human- 
ized" in IgE-mediated allergies may be valuable for development of therapeutic agents that tar- 
get the binding of IgE to its receptor. 
I 
gE antibodies, mast cells, and basophils play a pivotal role 
in allergic responses (1,  2).  Exposure of an individual to 
allergens  induces  the  production  of allergen-specific  IgE 
antibodies.  Mast  cells  and basophils bind  monomeric  IgE 
via the  high-affinity IgE receptor  (FceRI) 1 (1,  2).  Subse- 
quent  exposure  to  allergens  results  in  cross-linking of re- 
ceptor-bound IgE on mast cells  and basophils,  leading  to 
cellular activation and degranulation (1, 2). The release of a 
1Abbreviations used in this paper: BMMC, bone marrow-derived  mast cells; 
DNP, dinitrophenyl; FceRI, high-affinity  IgE receptor; NIP, nitro-iodo- 
hydroxyphenyl. 
variety of potent  mediators,  such  as  histamine,  proteases, 
and arachidonic acid metabolites, accounts for many of the 
symptoms in allergies (3, 4). 
Fc~RI has been suggested to be the key receptor in IgE- 
mediated  mast  cell  exocytosis  (1,  2).  This  notion  is  sup- 
ported by the finding that gene-targeted mice defective in 
Fc~RI expression are resistant to IgE-mediated anaphylaxis 
(5). Fc~RI is a tetrameric receptor composed of one ix, one 
[3, and two disulfide-linked ~/ chains (1).  Previous in vitro 
studies suggest that the binding of Fc~RI to IgE is mediated 
by the ix chain  (6-8).  However, cell surface expression of 
FceRI  requires  the  presence of all  three  subunits  (9,  10). 
Fc~RI is  expressed not  only on mast cells,  basophils,  and 
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11-15),  suggesting functions in addition to  mediating de- 
granulation. 
Human IgE is highly species specific and does not cross- 
react with rodent receptors  (6). To obtain an animal model 
capable  of responding to  human IgE  in allergic reactions, 
we generated transgenic mice expressing the human FceRI 
ci  chain.  Our  study  showed  that  the  human  oL  chain  of 
FceRI alone can reconstitute a functional receptor in mice. 
These transgenic mice can respond to human igE in aller- 
gic reactions. 
Materials and Methods 
Generation of Transgenic Mice Expressing the Human High-Affinity 
IgE Receptor oe Chain.  The human genomic clone for the FceRI 
c~ chain that we reported previously (16)  was used to  construct 
the transgene. An 11.4-kb human genomic DNA fragment in the 
clone covering the entire structural gene plus a  1.3-kb promoter 
region and a 4.2-kb 3'  flanking region was injected into mouse 
embryos to generate transgenic mice. The transgene in mice was 
confirmed by DNA hybridization. Mouse tail DNA was digested 
with EcoRI  and hybridized to  the  previously reported  human 
Fc~RI a  chain cDNA (16). Transgenic founders identified by hy- 
bridization were then bred with C57BL/6J mice to obtain trans- 
genic offspring for phenotypic and functional studies. 
Detection of Transgenic mRNA.  Total RNA was isolated from 
bone marrow-derived mast cells  (BMMC)  and from mouse or- 
gans according to the method described previously (16).  The or- 
gans  used  in  RNA  extraction  included  heart,  kidney,  liver, 
spleen, stomach, and skin. mRNA encoding the human FceRI 0~ 
chain was detected by Northern blot hybridization using the pre- 
viously reported human FceRI cr  chain cDNA as a probe  (16). 
mRNA for the mouse FceRl c~ chain was detected by the oligo- 
nucleotide 5'-TGTCAAAGGATCCATGGACTAAGATCATG- 
3', which is specific for exon 4 of the mouse FceRI o~ chain gene 
and does not cross-react with the transgenic mRNA. 
Mast Cell Cultures Derived  from Bone Marrows.  Mast cells from 
transgenic or C57BL/6J mice were prepared from bone marrow 
cells according to the method described by Razin et al.  (17).  In 
brief, bone marrow cells  were  collected from mouse femur and 
tibia  and  cultured  at  3  X  105  cells/ml  in  Razin's  medium 
(RPMI-1640  medium with  10%  FCS,  50  IxM  2-ME,  2  mM 
L-glutamine, 0.1 mM nonessential amino acids,  100 U/ml peni- 
cillin/streptomycin) supplemented with 20% WEHI-3B cell su- 
pernatant (American Type Culture Collection, Rockville, MD). 
Culture medium was changed weekly. After 3 wk in culture, the 
majority of the bone marrow cells  differentiated into mast cells. 
Mast cells were identified by the presence of basophilic granules 
in the cytoplasm of the cells after May Grtinwald/Giemsa staining. 
The Binding of IgE  to Mast  Cells Analyzed by Flow Cytometry. 
BMMC from transgenic and normal C57BL/6J  mice were used 
in flow cytometric analyses.  2  ￿  10  s BMMC in 50 IM of staining 
buffer (PBS  with 2%  FCS,  0.1% sodium azide) were  incubated 
for  1 h  at 4~  with 2.5  Dg of biotinylated human IgE  (Serotec 
Ltd.,  Oxford,  UK)  or mouse IgG (18),  followed by incubation 
with  streptavidin-phycoerythyrin  (Becton  Dickinson  &  Co., 
Mountain View, CA) for 20 min at 4~  Cell-bound IgE was an- 
alyzed via flow cytometry using the FACScan  |  program (Becton 
Dickinson & Co.). Specificity of human IgE binding was studied 
by  incubating BMMC  with  unbiotinylated human  IgE  before 
biotinylated human  IgE,  which  was  detected  by  streptavidin- 
phycoerythrin. The  possible cross-reactivity of mouse  IgE with 
human FceRI ~x chain (6)  in transgenic BMMC  was eliminated 
by pretreating BMMC with human IgE. 
FcERI Receptor-binding Assay  Using 12sI-IgE.  Binding assays of 
the  transgenic human FceRI  or  the  mouse  FceRI  on BMMC 
were performed using 12q-labeled human or mouse IgE, respec- 
tively. BMMC  (4 X  106 cells/ml) from transgenic or C57BL/6J 
mice were incubated at 37~  for 2 h with various concentrations 
of 12sI-IgE. Cell-bound IgE was separated from free lgE by cen- 
trifugation  of cells  through  0.3  ml  of an  oil  cushion  (dioctyl 
phthalate/dibutyl phthalate, 2:3 vol/vol) at  10,000 g for  1 min. 
The dissociation constants and the receptor numbers of FceRI on 
BMMC  were  calculated  from  values  of  the  bound  and  free 
12Sl-Igt according to the one binding equation (GraphPad Prism; 
GraphPad Software Inc.). 
Identification of FcERI Subunits Complexed with the Human FceRl 
ee Chain.  BMMC (107 cells) from transgenic or C57BL/6J mice 
were  incubated overnight with  1 Ixg/ml biotinylated human or 
mouse IgE in 5  ml of culture medium. Cells were  then solubi- 
lized in CHAPS buffer according to the method described by Ki- 
net et al.  (19) with some modifications. In brief, cells were lysed 
at 4~  in 0.2 ml of 10 mM CHAPS lysing buffer containing in- 
hibitors for phosphatases and proteolytic enzymes (l mM sodium 
orthovanadate, 12.5 mM sodium fluoride, 0.1 mM zinc chloride, 
2 mM EDTA, 2 mM EGTA, 1 mM PMSF, 20 btg/ml aprotinin, 
and  10  Ixg/ml leupeptin). IgE-bound FceRI in cell lysates  was 
recovered  by overnight incubation at  4~  with  0.1  ml packed 
volume  of precleared  avidin-conjugated agarose  beads  (Pierce 
Chemical  Co.,  Rockford,  lL).  The  IgE-FceRI  complex  was 
eluted in SDS-PAGE loading buffer,  separated on  12.5%  SDS- 
polyacrylamide gels  under reducing condition,  and  then  trans- 
ferred to  membranes (PolyScreen; New England Nuclear,  Bos- 
ton, MA).  The mouse FceRI  [3 and y  chains were  detected by 
the rat FceRI ~3 chain-specific mAb and the rabbit serum specific 
for the mouse Fc~RI y chain (20), respectively. Antibody binding 
was  detected with chemiluminescent reagents  (ECL kit; Amer- 
sham Corp., Arlington Heights, IL). 
Detection of Tyrosine Phosphorylation Triggered by Cross-linking of 
FcERI.  BMMC  (2  X  106  cells)  from  transgenic or C57BL/6J 
mice  were  incubated either  with  1  ~g/ml  of anti-nitro-iodo- 
hydroxyphenyl (NIP) human IgE  (Serotec Ltd.)  or anti-dinitro- 
phenyl (DNP) mouse IgE (18) for 2 h at 37~  in PBS. Cells were 
then rinsed with PBS and incubated for 2 min at 37~  with 40{} 
ng/ml NIP-BSA or DNP-BSA, respectively. BMMC incubated 
with  IgE but not with the  corresponding antigens were  used as 
negative controls. Cells were lysed in SDS-PAGE loading buffer, 
and proteins were separated and transferred to PolyScreen mem- 
branes as mentioned above. Phosphotyrosine was detected by the 
phosphotyrosine-specific mouse mAb 4G10 (Upstate Biotechnol- 
ogy, Inc., Lake Placid, NY), and antibody binding was detected 
with chemituminescent reagents from Amersham Corp. 
Detection of Tyrosine Phosphorflation on FcERI Subunits Triggered 
by the Cross-link of FcERl.  BMMC (107 cells) from transgenic or 
C57BL/6J mice were incubated overnight with 1 I~g/ml biotiny- 
lated anti-NIP human IgE  or anti-DNP mouse IgE in 5  ml of 
culture medium. The human or mouse IgE-coated BMMC were 
incubated with  1 Ixg/ml NIP-BSA or DNP-BSA, respectively, 
for  2  rain  at  37~  in  PBS  to  cross-link  IgE-bound  Fc~Rl. 
BMMC  were  solubilized in CHAPS buffer as described earlier, 
and IgE-bound FceRI  in cell lysates  was  recovered  by avidin- 
conjugated  agarose  beads.  Proteins  eluted  from  agarose  beads 
were  separated  by  reducing  S1)S-PAGE,  transferred  to  Poly- 
Screen membranes, and phosphotyrosines were detected. BMMC 
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not show  any signals in phosphotyrosine  detection,  confirming 
the specificity of the immunoprecipitations. 
IgE-mediated BMMC  Degranulation Detected by  the  Release of 
[3-Hexosaminidase.  Mast cell degranulation triggered by IgE and 
antigens was  carried out according to  the methods described by 
Yen et al.  (21).  BMMC  (5  X  I0  s cells) in 0.5 ml Tyrode's buffer 
were sensitized with 1 p~g/ml anti-NIP human IgE or anti-DNP 
mouse lgE for 1 h at 37~  After two rinses with Tyrode's buffer 
to remove unbound IgE, degranulation was triggered by 10-rain 
incubation with 50 ng/ml of the antigens, DNP,  or NIP conju- 
gated to  BSA.  Degranulation was  assayed  by measuring the en- 
zyme activity of released [3-hexosaminidase using a  colorimetric 
assay  (22).  Spontaneous 13-hexosaminidase release was  measured 
in samples not treated with IgE or antigen. Total 13-hexosamini- 
dase  was measured after lysing cells by sonication. Percentage of 
13-hexosaminidase release was calculated as: (13-hexosaminidase in 
supernatant/total [3-hexosaminidase) ￿  100. 
Passive Cutaneous Anaphylaxis.  Passive cutaneous anaphylaxis 
was  performed  in mice  according to  the  method  described by 
Saloga et al,  (23).  Transgenic mice and normal C57BL/6J  mice 
were injected intradermally on the dorsal side with 500 ng NIP- 
specific human lgE in 25 txl saline, and on the ventral side with 
25  Ixl saline for comparison. 2 h  later, NIP-BSA conjugates (0.5 
mg) plus 1% Evans blue in 250  txl saline i.v. was injected. Mice 
were killed 20 rain later, and cutaneous anaphylaxis was assessed 
visually by the blue dye leakage from blood vessels into the skin. 
Mouse IgE-mediated anaphylaxis was carried out similarly using 
DNP-specific mouse IgE and DNP-BSA. 
Results 
Mast Cell-specific  Transcription of the  Transgene Encoding  the 
Human FcERI ce Chain.  We previously cloned the human 
FceRI  ci  chain  gene  and  showed  that  the  human  gene  is 
similar in genomic structure to that of the rodent (16). The 
human FceRI 0r  chain gene spans over a  region of 5.9 kb 
and contains 5 exons. As shown in Fig.  1, an 11.4-kb DNA 
fragment covering the  entire human cx chain gene with an 
1.3-kb  promoter  region  and  a  4.2-kb  3'  flanking region 
was  used to generate transgenic mice.  Transcription of the 
transgene in different organs  and in mast cells from  trans- 
genic  mice  was  studied  by  Northern  blot  hybridization. 
Mast  cells  used  in  the  study  were  BMMC.  Transgenic 
mRNA  was  detected  only in BMMC,  but not in the  dif- 
ferent organs from transgenic mice (Fig. 2 A). Tissue distri- 
bution  of transgenic  mRNA  was  identical  to  that  tran- 
scribed  by  the  endogenous  mouse  Fc~RI  ci  chain  gene 
(Fig.  2  B).  The  data  suggest that  the  1.3-kb  promoter  re- 
gion of the human Fc~RI cl chain gene is sufficient for reg- 
ulating proper tissue-specific expression. 
Cell  Surface Expression  of the  Human  FcERI cr  Chain  on 
Transgenic Mast Cells.  Cell surface expression of the trans- 
genic human Fc~RI ci chain on mast cells was  assessed  by 
its specific binding to  human IgE.  Human  IgE was shown 
to  bind to  BMMC  from  transgenic mice,  but not  to  that 
from C57BL/6J mice in flow cytometric analyses (Fig. 3,  C 
and D).  The  binding of biotinylated human  IgE  to  trans- 
genic BMMC  was  completely  abrogated  when  cells were 
pretreated  with  unbiotinylated human lgE,  suggesting the 
Figure 1.  Expression of the human Fc{RI ~x chain transgene. (A) The 
transgene was an 11.4-kb human genomic DNA fragment containing  the 
entire structural gene with 5 exons (black blocks), a 1.3-kb promoter re- 
gion, and a 4.2-kb 3' flanking region. The location of the codons ATG 
and TGA, indicating the start and the end sites of translation, respectively, 
are shown. The transgene for embryo injection  was recovered by SacI di- 
gestion. The SacI site at the 5' end of the DNA fragment is derived from 
the plasmid vector. (B) Transgenic mice were identified by Southern blot 
hybridization.  Tail  genomic  DNA samples were  digested with EcoRI, 
and the  transgene  in transgenic  (TG) mice  was  detected  by a  human 
Fc~RI (x chain cDNA probe (16). The specificity of the DNA probe was 
confirmed by the positive DNA bands shown in the DNA sample from a 
human lymphoblastic cell line (IM9), but not in that from the nontrans- 
genic C57BL/6J mouse (B6). 
specificity in the binding to human IgE (Fig. 3  E). 125I-human 
IgE  was  also  used in receptor-binding assays  to  determine 
the  binding  affinity  of  transgenic  FcERI  toward  human 
IgE. As shown in Table 1, the number of transgenic FceRI 
on BMMC  was 4.7  X  104/ce11,  and the human IgE dissoci- 
ation constant was 6.4 nM.  These values were  comparable 
to  those  of the mousee  Fc{RI  (1.8  X  10S/cell,  Ka  =  2.19 
nM)  determined in the same  experiment using mouse IgE 
(Table 1), and were also consistent with the values reported 
previously for  human or  mouse  FceRI  on  mast  cells  (24, 
25).  Taken together,  the specific binding of human IgE to 
BMMC  from transgenic mice as shown in flow cytometric 
analyses  and  in  12sI-IgE-binding assays  confirms  the  cell 
surface expression of the human FceRI oL chain. 
Figure  2.  Tissue-specific  expres- 
sion  of FceRI cl chain mRNA from 
the human transgene. (A) Total RNA 
samples from different organs (t5 p~g) 
and from  BMMC  (7.5 ~zg) of trans- 
genic mice were detected by a human 
FceRI  cx  chain  cDNA  probe.  (B) 
Mouse  FceRI  c~  chain  mRNA  was 
detected by an oligonucleotide specific 
for  the  mouse  gene  within exon  4. 
RNA  samples (35  ~g)  from  the 
human  KU812  mast  cell  line  (41) 
and  from  BMMC  of nontransgenic 
C57BL/6J  mice  (B6) were  used  as 
positive  controls  for  hmnan  and 
mouse FceRl 0t chain mRNA, respec- 
tively. 
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Figure  3.  Cell  surface expression  of  the 
transgenic human Fc~RI ~x chain on mast cells 
from transgenic mice. (A and B) Histograms of 
cell-bound mouse IgE on BMMC from trans- 
genic  (Tg) mice  and nontransgenic  C57BL/6J 
mice  are shown.  These  BMMC  samples have 
been treated with 2.5 p.g unbiotinylated human 
IgE for 20 min at 4~  before binding to mouse 
IgE. (C and D)  Histograms of cell-bound hu- 
man IgE on BMMC are shown.  (E) The histo- 
gram  of cell-bound human IgE on the  trans- 
genic  BMMC  pretreated  with  unbiotinylated 
human IgE is shown. Cells stained with strepta- 
vidin-phycoerythrin alone were  used as nega- 
tive controls (gray histogram) to compare to spe- 
cific IgE binding (black histogram). Cell-bound 
IgE was analyzed by flow cytometry  using the 
FACScan  |  program. 
Mouse  FceRI  on  mast  cells was  assayed  similarly using 
mouse IgE. Mast ceils from both transgenic and C57BL/6J 
mice were shown to bind to mouse IgE in flow cytometric 
analyses (Fig.  3,  A  and B).  However,  the  amount of cell- 
bound mouse IgE on transgenic mast cells was less than that 
on the nontransgenic BMMC.  Consistent with this finding, 
125I-IgE-binding studies also showed that mouse FceRI re- 
ceptor number on transgenic BMMC  was reduced, whereas 
its  mouse  IgE-binding affinity was  unchanged  (Table  1). 
The results suggest that the cell surface expression of mouse 
FceRI was reduced on BMMC  from transgenic mice. This 
decrease  in  mouse  FceRI  level  on  transgenic  mast  cells 
could be  due to  the  competition between the  human and 
mouse  (x  chains  in  coupling with  the  mouse  y  and/or  13 
chains. The possibility that the human FceRI 0t chain forms 
a  chimeric receptor with mouse y  and/or [3 chains has also 
been  suggested  by  previous  transfection  studies  (9,  10, 
26-28). 
The  Transgenic  Human  FcERI ee  Chain  Is  Complexed  with 
the Mouse [3 and 3, Chains.  The human FceRI 0L chain has 
been shown in transfected cells to require at least the ot and 
y  chains  for  cell  surface  expression  (10,  26-28).  In  this 
transgenic  model,  proteins  that  are  complexed  with  the 
transgenic human FceRI cx chain were  analyzed in immu- 
noprecipitation  studies.  To  maintain  the  integrity  of the 
FcERI receptor complex, BMMC  were lysed with CHAPS 
buffer  according  to  the  method  of Kinet  et  al.  (19).  The 
transgenic human FceRI or the endogenous mouse FceRI 
was immunoprecipitated via its binding to human or mouse 
IgE,  respectively.  The  mAb  specific  for  the  rat  Fc~RI  [3 
chain detected the mouse 13 chain in mouse FceRI immu- 
noprecipitates  with .an apparent  molecular mass  of 30  kD 
(Fig.  4).  Interestingly, the  mouse  FceRI  13  chain was  also 
present in the transgenic human Fc{RI immunoprecipitates 
(Fig. 4).  The mouse Fc~RI ",/chain, which was ~10  kD in 
size,  was  detected  with  rabbit sera  specific  for  the  mouse 
Fc~RI  ~/  chain  (20).  Similarly,  the  mouse  y  chain  was 
found  in  both  the  immunoprecipitates  of the  transgenic 
human  FceRI  and the  mouse  FceRI  (Fig.  4).  The  results 
demonstrated  that  the  human  Fc~RI  et  chain  is  coupled 
with  both  the  mouse  13  and "y  chains  to  form  a  chimeric 
human/mouse receptor. 
Normal  Tyrosine  Phosphorylation  Triggered  by  Cross-linking 
the  Transgenic FceRI.  Activation and degranulation of mast 
cells  via  FceRI  aggregation  has  been  shown  to  involve 
early  signaling  events  including activation  of protein  ty- 
rosine kinases (29-33). The function of the transgenic FceRI 
in initiating tyrosine phosphorylation in BMMC  was inves- 
tigated.  Transgenic human Fc~RI was cross-linked by first 
binding to anti-NIP human IgE (34), followed by interact- 
ing with the multivalent antigen NIP-BSA. Mouse endog- 
enous Fc~RI was aggregated similarly by anti-DNP mouse 
IgE  (18)  and DNP-BSA.  Significant induction in tyrosine 
Table 1.  Number of Human FcERI on Transgenic BMMC and 
Its Binding AflTnity to Human IgE 
BMMC  IgE  Receptor/cell  Kd 
nM 
Transgenic  Human  4.7 X  104  6.40 
Mouse  4.1  X  10  4  2.93 
C57BL/6J  Mouse  1.8  X  10  s  2.19 
Figure 4.  The  transgenic human 
FceRI  (x  chain  is  complexed  with 
the mouse  ~  and 3'  chains. Mouse 
FceRI from C57BL/6J (Bt) BMMC 
or  human  Fc~RI  from  transgenic 
(Tg)  BMMC  was  immunoprecipi- 
tated with mouse IgE (m) or human 
IgE (h) as described in Materials and 
Methods. The mouse FceRI ~ chain 
was  detected  with  anti-rat  13  mAb 
(20), whereas  the 3'  chain was  de- 
tected by using the 3' chain-specific 
rabbit serum (21). 
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of mouse  FceRI  on  BMMC  from  transgenic  or  control 
C57BL/6J  mice  (Fig.  5).  Human  IgE and  NIP-BSA also 
triggered  pronounced  tyrosine  phosphorylations  in  trans- 
genic  BMMC  but  not  in  C57BL/6J  BMMC,  suggesting 
that  the  human  IgE-induced signaling events were  medi- 
ated  specifically by the  transgenir  human  FceRI  (Fig.  5). 
The patterns  of phosphorylated proteins induced by aggre- 
gation of the  transgenic  human FceRI or the  endogenous 
mouse FceRI appeared to be similar (Fig. 5). 
Recent  reports  have  shown  that  aggregation  of Fc~RI 
leads to significant tyrosine phosphorylation of the 13 and ~/ 
subunits,  which recruit other signaling molecules for cellu- 
lar activation (29, 31). Tyrosine-phosphorylated proteins in 
immunoprecipitates of the transgenic FceRI were therefore 
examined.  Proteins  of ~30  and  10 kD,  which correspond 
by  size  to  the  FceRI  [3  and  y  chains,  respectively,  were 
barely detectable  in  immunoprecipitates  of uncross-linked 
mouse FceRI (Fig. 6).  Upon aggregation of mouse Fc{RI, 
these  proteins  were  dramatically  enhanced  in  tyrosine 
phosphorylation  (Fig.  6).  Cross-linking  of the  transgenic 
FceRI also showed significant tyrosine phosphorylation of 
the 30 and  10 kDa proteins  (Fig.  6).  Human IgE does not 
bind to mouse Fc~RI and therefore had no effect on Fc~RI 
on  nontransgenic  BMMC.  Taken  together,  the  data  sug- 
gest that the transgenic  human Fc~RI is functional in trig- 
gering mast cell activation. The coupling of mouse [3 and y 
chains with the transgenic human ot chain appears not only 
important for cell surface expression, but also for the proper 
function of the chimeric receptor. 
Degranulation  of Transgenic Mast  Cells Triggered by  Cross- 
linking  the  Human  FcERI  ee  Chain.  With  this  transgenic 
model, we address the question whether the human/mouse 
chimeric  receptor  is  competent  in  eliciting  mast  cell  de- 
granulation.  Mast cells were prepared from transgenic mice, 
and degranulation was triggered by first allowing the bind- 
ing of IgE to Fc~RI on mast cells,  followed by cross-link- 
ing receptor-bound IgE with a multivalent antigen. Release 
of [3-hexosaminidase upon degranuladon was measured.  The 
NIP-specific human IgE and NIP-BSA triggered a specific 
release  of [3-hexosaminidase  from transgenic  BMMC,  but 
not from control C57BL/6J  BMMC  (Fig.  7).  The  DNP- 
Figure  5.  Tyrosine phosphoryla- 
tion of cellular proteins induced by 
cross-linking of  transgenic FceRl. 
FceRl  on BMMC from C57BL/6J 
(B6) and transgenic (Tg) mice were 
cross-linked (X)  by mouse IgE (m) 
or human IgE (h) plus their specific 
antigens  as  described in  Materials 
and Methods. Uncross-linked con- 
trols were samples treated with IgE 
but not the antigens. Total cell ly- 
sates  were  prepared  2  rain after 
cross-linking  the  receptors,  and 
phosphotyrosines were detected on 
Western blots. 
Figure 6.  Tyrosine  phosphor- 
ylation of the  mouse ~  and  ~/ 
chains in  the  transgenic FceRI 
upon  receptor  aggregation. 
Fc~RI on BMMC from C57BL/ 
6J  (B6) or transgenic (Tg) mice 
were cross-linked (X) by mouse 
IgE (m)  or human IgE (h)  plus 
their  specific  antigens.  FceRI 
was  then  immunoprecipitated, 
and  phosphotyrosines were  de- 
tected as  described in  Materials 
and  Methods.  Uncross-linked 
mouse Fc~RI was also used as a 
control for comparison. 
specific mouse  IgE and DNP-BSA induced degranulation 
of BMMC  from both  transgenic  and  nontransgenic  mice 
(Fig. 7). The results indicate that the FceRI with the trans- 
genic human  o~ chain  is  responding  to  human  IgE, and is 
functional in mediating  murine  mast  cell  exocytosis.  Mast 
cells  from  transgenic  mice,  however,  can  still  respond  to 
mouse IgE in exocytosis. 
Passive Cutaneous Anaphylaxis of Transgenic Mice Induced by 
Human IgE and Antigens.  To assess whether the transgenic 
Fc~RI with the human o~ chain can respond to human lgE 
in  mast  cell  degranulation  in vivo, passive  cutaneous  ana- 
phylaxis was carried out in transgenic mice. Mice were in- 
tradermally  injected  wtih  human  or mouse  IgE,  followed 
by  intravenous  injection  of antigens  and  Evans  blue.  In 
transgenic  mice,  human  IgE and its  antigen  NIP-BSA in- 
duced a specific leak of Evans blue into the skin at the site 
ofintradermal injection.  This blue dye leakage was not ob- 
served  in control C57BL/6J  mice  (Fig.  8).  The  extravasa- 
tion of the dye is a result of blood vessel dilation,  which is 
induced by mediators released from mast cells in degranula- 
tion.  Mouse  monoclonal  IgE  and  its  antigen  DNP-BSA 
caused a similar leak of Evans blue in both transgenic mice 
and control C57BL/6J mice (Fig. 8).  The results provide a 
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Figure 7.  Human IgE plus antigens mediated degranulation of mast 
cells from transgenic mice. ~-Hexosaminidase released from transgenic 
BMMC (black  column) and nontransgenic C57BL/6J BMMC (gray  column) 
were induced by human or mouse monoclonal lgE plus their specific an- 
tigens,  NIP-BSA  or  DNP-BSA,  respectively. The  value of ]3-hex- 
osaminidase release is the average of  three experiments. Error bars indicate 
SEM. In nontransgenic BMMC, 13-hexosaminidase release induced by 
human IgE is not significantly different from spontaneous release (p = 
0.41 by Wilcoxin rank sum test). 
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spond to human IgE in anaphylaxis. 
Discussion 
Human FceRI expression on the cell surface is known to 
require  at least the ot and y  chains (10,  26-28). iThe ability 
of the "y chain to allow surface expression  of the  Fc~RI 
chain is analogous to the role of the ~ chains in the expres- 
sion  of the  TCR-CD3  complex,  although  the  molecular 
mechanism of the FceRI assembly is still  unclear. Both the 
FceRI  c~  and  y  chains  are  highly  conserved  at  the  trans- 
membrane  portions,  which  are  suggested  to  be  important 
for proper  assembly  of the  FceRI  receptor  complex  (10, 
28).  In contrast,  the role of the 13 chain for cell surface ex- 
pression  and activation of human  FceRI has been unclear. 
Questions  have therefore  been raised regarding to the im- 
portance of the Fc~RI 13 chain in humans and the possible 
difference  in  FceR1  receptor  complex  between  humans 
and  rodents.  We  have  demonstrated  here  in  a  transgenic 
model that the transgenic FceRI, which elicits normal mast 
cell  activation  and  degranulation,  is  composed of the  hu- 
man c~ chain and the mouse 13 and y  chains.  The data sug- 
gest that the 13 chain may play a role in the biological func- 
tions  of FceRI.  The  importance  of the  13  chain  has  also 
been suggested by the finding that it is also associated with 
the IgG Fc receptor type III, which mediates effector func- 
tions similar to that of FceRI (35).  A  correlation of muta- 
tions on the FceRI [3 chain gene with atopic dermatitis has 
also been reported recently (36, 37). 
The transgenic  FceRI in which only the ot chain was of 
human origin was shown to bind to human IgE specifically. 
This  is  consistent  with  previous  in  vitro  studies  showing 
that the ot chain  confers entirely the  IgE-binding specific- 
Figure 8.  Human IgE plus an- 
tigen induced passive cutaneous 
anaphylaxis in  transgenic mice. 
Passive cutaneous anaphylaxis in 
transgenic  (Tg) and  C57BL/6J 
control  (C57BL/6)  mice was 
triggered by  mouse IgE  (mlgE) 
or human lgE  (hlgE) plus their 
specific antigens as  described in 
Materials and Methods. 
ity, whereas the 13 and y  chains are responsible for signaling 
events  (6,  11,  29,  31,  38,  39).  The extracellular portion of 
the FceRI ~  chain has been shown to display less conserva- 
tion between species (10). This structural diversity could be 
responsible for the species specificity seen in IgE-FceRI in- 
teraction. 
The  proper  assembly  and  coordination  of the  different 
subunits  of FceRI is  essential  for its  function  in triggering 
mast  cell  degranulation  (1).  In  this  regard,  the  FceRI  c~ 
chain receives external signals  through IgE binding, whereas 
the FceRI y  chain plays a critical role in signal transduction 
(11, 29, 31, 38, 39). Although the human FceRI o~ chain in 
association with mouse y  chains has been shown to trigger 
limited  early signaling events  in mast cell lines,  the induc- 
tion  of cellular  degranulation  has  not  been  demonstrated 
(26,  39,  40).  We  showed with  this  transgenic  model  that 
the human/mouse  chimeric FceRI is functional in mediat- 
ing mast cell activation and degranulation.  The results sug- 
gest that the proper conformation of the receptor complex 
is maintained in the transgenic FceRI. 
Allergic diseases  affect 20% of the population and are an 
important cause of morbidity and mortality.  The cell type- 
specific expression and the key role in mast cell exocytosis 
make FceRI an attractive drug target for treatment of IgE- 
dependent allergies.  However, animal studies are limited by 
the  species  specificity in  IgE-FceRI interaction.  We  have 
demonstrated  here  in  a  transgenic  model  that  the  human 
FceRI  o~  chain  not  only confers  the  specificity in  human 
IgE binding but also can reconstitute a functional FceRI to 
trigger mast cell degranulation  in vitro and in vivo. These 
transgenic  mice  with  a  "humanized"  FceRI  could  be  a 
valuable model for developing drugs that block human IgE 
from binding to its receptor. 
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